Outlook Therapeutics reported a preliminary cash balance of approximately $11.2 million for its third quarter ended June 30, 2026. Despite the July 2026 FDA approval of LYTENAVA for wet AMD, the company expressed substantial doubt about its ability to continue as a going concern, indicating that current capital is only sufficient to fund operations into September 2026.
Key Highlights
- Reported a preliminary cash and cash equivalents position of $11.2 million as of June 30, 2026.
- Warned of critical liquidity constraints with a cash runway extending only through September 2026.
- Carries $19.8 million in outstanding debt under an unsecured note to Atlas Sciences, with $3.0 million quarterly redemptions scheduled to begin in September 2026.
- Terminated a May 2026 ATM offering prospectus supplement while U.S. commercial launch plans for LYTENAVA remain pending.